OBJECTIVES: Peritoneal metastasis is one of the major sites of disease progression of pancreatic cancer. There have been few trials in the second-line setting after gemcitabine failure because patients can hardly be candidates for chemotherapy after failure in the first-line chemotherapy, especially those with malignant ascites. The safety and efficacy of weekly paclitaxel therapy was evaluated for pancreatic cancer patients with malignant ascites in this retrospective study. METHODS: The subjects of this retrospective study were 23 advanced pancreatic cancer patients with malignant ascites who received weekly paclitaxel therapy after gemcitabine failure. Paclitaxel (80 mg/m(2), div. for 1 h) was administered on Days 1, 8 and 15, every 4 weeks. RESULTS: While the disease control rate was 35%, decrease of ascites was obtained in 30% of the patients and ascites control rate was 61%. The median survival time was 101 days. Toxicities were mild, although one treatment-related death occurred. CONCLUSIONS: Weekly paclitaxel therapy may be useful treatment option for pancreatic cancer patients with malignant ascites after gemcitabine failure.
OBJECTIVES: Peritoneal metastasis is one of the major sites of disease progression of pancreatic cancer. There have been few trials in the second-line setting after gemcitabine failure because patients can hardly be candidates for chemotherapy after failure in the first-line chemotherapy, especially those with malignant ascites. The safety and efficacy of weekly paclitaxel therapy was evaluated for pancreatic cancerpatients with malignant ascites in this retrospective study. METHODS: The subjects of this retrospective study were 23 advanced pancreatic cancerpatients with malignant ascites who received weekly paclitaxel therapy after gemcitabine failure. Paclitaxel (80 mg/m(2), div. for 1 h) was administered on Days 1, 8 and 15, every 4 weeks. RESULTS: While the disease control rate was 35%, decrease of ascites was obtained in 30% of the patients and ascites control rate was 61%. The median survival time was 101 days. Toxicities were mild, although one treatment-related death occurred. CONCLUSIONS: Weekly paclitaxel therapy may be useful treatment option for pancreatic cancerpatients with malignant ascites after gemcitabine failure.
Authors: S Yamada; T Fujii; T Yamamoto; H Takami; I Yoshioka; S Yamaki; F Sonohara; K Shibuya; F Motoi; S Hirano; Y Murakami; H Inoue; M Hayashi; K Murotani; J Kitayama; H Ishikawa; Y Kodera; M Sekimoto; S Satoi Journal: Br J Surg Date: 2020-07-07 Impact factor: 6.939